-Divis Research Center (DRC) established.
-DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors.
-Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year.
-Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations.
-SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant.
-European Directorate gives a Certificate of Suitability (CoS) for Naproxen produced at Divis Laboratories.
-US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems).
-BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems).
-Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam.
-Divis opens a new research center christened DRC-Vizag for fundamental research in selected niche business core segments.
-Went for IPO and listed on stock exchanges BSE, NSE and HSE.
-Divi's Laboratorie receives Certificate of Substantiability from the council of Europe
-Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization.
- Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004.
-US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483.
-Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006.
-US-FDA inspects the Visakhapatnam(Unit-2) for the first time.
- The Company has splits its face value from Rs10/- to Rs2/-.
-Third US-FDA inspection for Choutuppal(Unit-1).